PRESS

Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced that it is participating in the BIO International Convention 2026 in San Diego.

Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced the expansion of its Series C financing and the initial close of its Series C+ financing round.

Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the ChinaBIO in Shanghai.